ALT5 Sigma Q4 fintech revenue $5.4M; 1,000+ customers; appoints COO

AI Financial Corp

2025-Q1 EPS reported -$0.18 revenue$5,514,000

Q4 fintech revenue $5.42M; full-year fintech revenue (from May 15) $12.53M; adjusted EBITDA ~$1.03M.
Fintech segment full-year gross margin 50.2%; adjusted EBITDA 18.2%; working capital improved $4.5M QoQ.
Customer base exceeded 1,000; cash and equivalents $7.18M as of Dec 28, 2024.
Ron Pitters appointed COO; board approved separation of fintech and biotech (Alyea) into independent entities.
Alyea Therapeutics preparing for standalone listing; key leadership team appointed including Dr. Amol Soin CEO.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001628280-25-015586
form_type: 8-K
ticker: AIFC
cik: 0000862861
company_name: AI Financial Corp
filed_at: 2025-03-31T23:59:59+00:00
discovered_at: 2026-05-14T18:03:06.543134+00:00
generated_at: 2026-05-24T02:42:52.051380+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: positive
materiality_score: 0.75
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001628280-25-015586
json_url: https://secwatch.observer/filing/0001628280-25-015586.json
markdown_url: https://secwatch.observer/filing/0001628280-25-015586.md
text_url: https://secwatch.observer/filing/0001628280-25-015586.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/862861/000162828025015586/0001628280-25-015586-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/862861/000162828025015586/jan-20250328.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001628280-25-015586

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.